Our study confirms the high effectiveness and favorable safety profile of IL-17A inhibitors in pediatric psoriasis. The low rate of hypothetical RCT eligibility highlights a gap between trial populations and clinical practice, underscoring the vital role of daily-practice data in guiding treatment.
FBI Reform - fbireform.comFBI Reform - fbireform.com - The News And Times